1.Laksono, BM et al. (2016) Measles virus host invasion and pathogenesis. Viruses 8, 210.
2.Moss, WJ and Griffin, DE (2012) Measles. The Lancet 379, 153–164.
3.Mina, MJ et al. (2015) Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 348, 694–699.
4.Duke, T and Mgone, CS (2003) Measles: not just another viral exanthem. The Lancet 361, 763–773.
5.Patel, MK et al. (2016) Progress toward regional measles elimination – worldwide, 2000–2015. Morbidity and Mortality Weekly Report 65, 1228–1233.
6.Harpaz, R (2004) Completeness of measles case reporting: review of estimates for the United States. Journal of Infectious Diseases 189, S185–S190.
7.Papania, MJ and Strebel, PM (2005) Measles surveillance: the importance of finding the tip of the iceberg. The Lancet 365, 100–101.
8.Sydenstricker, E (1926). The reporting of notifiable diseases in a typical small city. Public Health Reports 41, 2186–2191.
9.Trottier, H, Carabin, H and Philippe, P (2006) Measles, pertussis, rubella and mumps completeness of reporting. Literature review of estimates for industrialized countries. Revue d'Epidemiologie et de Sante Publique 54, 27–39.
10.Ewert, DP et al. (1995) Measles reporting completeness during a community-wide epidemic in inner-city Los Angeles. Public Health Reports 110, 161–165.
11.Cherry, JD et al. (1972) Urban measles in the vaccine era: a clinical, epidemiologic, and serologic study. Journal of Pediatrics 81, 217–230.
12.van Isterdael, CE et al. (2004) Measles incidence estimations based on the notification by general practitioners were suboptimal. Journal of Clinical Epidemiology 57, 633–637.
13.McDonnell, LF and Jorm, LR (1994) Measles epidemic in western Sydney. New South Wales Public Health Bulletin 5, 59–60.
14.Fine, PE and Clarkson, JA (1982) Measles in England and Wales – II: The impact of the measles vaccination programme on the distribution of immunity in the population. International Journal of Epidemiology 11, 15–25.
15.Wallinga, J, Teunis, P and Kretzschmar, M (2003) Reconstruction of measles dynamics in a vaccinated population. Vaccine 21, 2643–2650.
16.Woudenberg, T et al. (2017) Large measles epidemic in the Netherlands, May 2013 to March 2014: changing epidemiology. Eurosurveillance 22, pii = 30443.
17.Ruijs, WL et al. (2012) Measuring vaccination coverage in a hard to reach minority. European Journal of Public Health 22, 359–364.
18.van den Hof, S, Conyn-van Spaendonck, MA and van Steenbergen, JE (2002) Measles epidemic in the Netherlands, 1999–2000. Journal of Infectious Diseases 186, 1483–1486.
20.Kremer, JR and Muller, CP (2005) Evaluation of commercial assay detecting specific immunoglobulin g in oral fluid for determining measles immunity in vaccines. Clinical and Diagnostic Laboratory Immunology 12, 668–670.
21.Vainio, K et al. (2008) Detection of measles- and mumps-specific IgG antibodies in paired serum and oral fluid samples from Norwegian conscripts. European Journal of Clinical Microbiology and Infectious Diseases 27, 461–465.
22.Nokes, DJ et al. (2001) Has oral fluid the potential to replace serum for the evaluation of population immunity levels? A study of measles, rubella and hepatitis B in rural Ethiopia. Bulletin of the World Health Organization 79, 588–595.
23.Leite, RD, Barreto, JL and Sousa, AQ (2015) Measles reemergence in Ceara, Northeast Brazil, 15 years after elimination. Emerging Infectious Diseases 21, 1681–1683.
24.De Serres, G et al. (2013) Largest measles epidemic in North America in a decade-Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events. Journal of Infectious Diseases 207, 990–998.
25.Hall, V et al. (2017) Measles outbreak – Minnesota April-May 2017. Morbidity and Mortality Weekly Report 66, 713–717.